Products Description
English name：The cholesterol drug Alirocumab
CAS number：1245916-14-6
Related: Drug substance; mAb 3; chemical reagent
Constitutional formula:
The cholesterol drug Alirocumab properties
Morphological ：liquid
Color：Colourless to light yellow
condition of storage： Store at 4°C, Do not freeze
Use and synthesis methods
MAb：
Allicuumab acts by inhibiting the PCSK 9 protein, where PCSK 9 binds to the low-density lipoprotein receptor (LDLR) (removing cholesterol from the circulation), and this Chemicalbook binding leads to the degradation of the receptor and the removal of less LDL cholesterol from the circulation. Inhibition of PCSK 9 prevents receptor degradation and promotes the removal of LDL cholesterol from the circulation.
Bioactivity:
Aliiciumab is a human monoclonal antibody that binds to the proprotein convertase subtilis protease type kexin9 (PCSK 9). PCSK 9 binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation in the liver. LDLR is the major receptor for clearing Chemicalbook circulating LDL, so the reduction of LDLR levels by PCSK 9 leads to increased blood levels of LDL-C. By inhibiting the binding of PCSK 9 to the LDLR, alirocumab increases the amount of LDLR available to achieve LDL clearance, thereby reducing the LDL-C levels
Indication:
Aliciumab is a PCSK 9 (proproteinConvertaseSubtilisinKexinType9) inhibitor antibody for dietary and maximum Chemicalbook tolerated statin treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional LDL-cholesterol reduction (LDL-C).
New mAb drugs:
On July 24,2015, the FDA approved Sanofi PCSK 9 inhibitor drug Alirocumab injection as Praluent. PCSK 9 is the proprotein convertase Chemicalbook subtilisin 9 protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C) from the blood, and LDL-C is recognized as a major risk factor for cardiovascular disease. The Praluent concentration in the injection pen was 75 mg/ml / 150 mg/ml.
Security information ：
Toxic material data：1245916-14-6(Hazardous Substances Data)
Hot Tags: study of alirocumab for hypercholesterolemia, China study of alirocumab for hypercholesterolemia suppliers, Rastuzumab Emtansine For Advanced Breast Cancer, Mepolizumab Monoclonal Antibody for Severe Asthma, Atezolizumab cancer drug, Ocrelizumab Is Being Studied in Multiple Sclerosis, Lecanemab Monoclonal Antibody for Alzheimer s Disease, bio similar drugs
